Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Market Closed 11-06 16:00:00 EST

15.20

+2.12

+16.21%

盘后15.15

-0.05-0.33%

19:59 EST

High15.21	Low13.53	Vol7.90M
Open13.79	D1 Closing13.08	Amplitude12.83%
Mkt Cap2.77B	Tradable Cap2.62B	Total Shares182.32M
T/O115.03M	T/O Rate4.58%	Tradable Shares172.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":15.2,"timestamp":1793998800000,"preClose":13.08,"halted":0,"volume":7897218,"hourTrading":{"tag":"盘后","latestPrice":15.15,"preClose":15.2,"latestTime":"19:59 EST","volume":75592,"amount":1146391.2729,"timestamp":1794013162295,"change":-0.05,"changeRate":-0.003289,"amplitude":0.025},"delay":0,"changeRate":0.16207951070336385,"floatShares":172573639,"shares":182320306,"eps":-0.102003,"marketStatus":"Market Closed","change":2.12,"latestTime":"11-06 16:00:00 EST","open":13.79,"high":15.21,"low":13.5315,"amount":115033254.450618,"amplitude":0.128326,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.102003,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":13.08,"preHourTrading":{"tag":"盘前","latestPrice":13.66,"preClose":13.08,"latestTime":"09:29 EST","volume":30060,"amount":397520.32373999996,"timestamp":1793975399999,"change":0.58,"changeRate":0.044343,"amplitude":0.079511},"postHourTrading":{"tag":"盘后","latestPrice":15.15,"preClose":15.2,"latestTime":"19:59 EST","volume":75592,"amount":1146391.2729,"timestamp":1794013162295,"change":-0.05,"changeRate":-0.003289,"amplitude":0.025},"volumeRatio":1.7241082849115335,"impliedVol":1.0005,"impliedVolPercentile":0.6892},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2681894704","title":"Xeris Biopharma President and COO Kevin McCulloch Reports Sale of Common Shares Worth $312,215","url":"https://stock-news.laohu8.com/highlight/detail?id=2681894704","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681894704?lang=en_us&edition=fundamental","pubTime":"2026-11-07 05:33","pubTimestamp":1794000833,"startTime":"0","endTime":"0","summary":"Xeris Biopharma President and COO Kevin McCulloch Reports Sale of Common Shares Worth $312,215Xeris Biopharma President and Chief Operating Officer Kevin McCulloch sold 25,000 common shares on Novembe","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDL72zYHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma President and COO Kevin McCulloch Reports Sale of Common Shares Worth $312,215","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681893147","title":"Oppenheimer Adjusts Xeris Biopharma PT to $21 From $18, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2681893147","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681893147?lang=en_us&edition=fundamental","pubTime":"2026-11-07 00:09","pubTimestamp":1793981377,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (XERS) has an average rating of buy and mean price target of $11.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681860130","title":"Xeris Pharmaceuticals (XERS) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2681860130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681860130?lang=en_us&edition=fundamental","pubTime":"2026-11-06 23:00","pubTimestamp":1793977254,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Leland Gershell reiterated a Buy rating on Xeris Pharmaceuticals today and set a price target of $21.00. Gershell covers the He...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xeris-pharmaceuticals-xers-gets-a-buy-from-oppenheimer-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xeris-pharmaceuticals-xers-gets-a-buy-from-oppenheimer-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681674008","title":"Xeris Biopharma Price Target Raised to $12.00/Share from $8.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2681674008","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681674008?lang=en_us&edition=fundamental","pubTime":"2026-11-06 22:38","pubTimestamp":1793975880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681586835","title":"Xeris Biopharma price target raised to $18 from $10 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2681586835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681586835?lang=en_us&edition=fundamental","pubTime":"2026-11-06 19:15","pubTimestamp":1793963738,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $10 and keeps a Buy rating on the share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-18-from-10-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-18-from-10-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681885093","title":"NASDAQ Net Change Percentage Gainers & Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2681885093","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681885093?lang=en_us&edition=fundamental","pubTime":"2026-11-06 06:44","pubTimestamp":1793918640,"startTime":"0","endTime":"0","summary":"Tradr 2X Long APP Daily     APPX     14.52     5.58     62.42     9,252,545. GrShr 2x Shrt SK Hynix      SKDD     12.46     2.77     28.59     6,188,718. Defiance Tgt 2x Shrt QBTS   QBTZ     45.82     9.57     26.40       182,962. Encore Capital Group        ECPG    126.17    26.24     26.26       707,720. Defiance Tgt 2x Shrt RGTI   RGTZ     31.58     6.42     25.52       267,263. GrShr 2x Long BTDR Daily    BTDL      2.80    -1.63    -36.74       258,084. Leverage 2X Lg AMD Dly      AMDG     51.89   -27.80    -34.88       186,123. GrShr 2x Long AMD Daily     AMDL     30.79   -16.48    -34.86     8,465,474. Leverage 2x Lg FIG Dly      FIGG     10.72    -5.73    -34.85       256,091. Direxion AMD Bull 2X        AMUU    109.61   -58.38    -34.75       243,522. Direxion MU Bull 2X          MUU     12.62    -6.61    -34.37    85,263,053. GrShr 2x Long MU Daily      MULL      8.78    -4.57    -34.23    16,338,205. Only includes stocks with a prior day close of $2 a share. or higher and at ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","APP","SKHQ","ADMA","LU0353189680.USD","MUZ","LU1861215975.USD","07709","AMDL","APPX","FIG","CLOD","BK4009","SK","IE00B19Z9P08.USD","MU","RGTZ","QUA","LU2360106780.USD","FBT","LU0154236417.USD","LU1852331112.SGD","AMD","LU2250418816.HKD","IE00B19Z9Z06.USD","LU2063271972.USD","XDAT","SKHN","MUYY","AMDD","DAMD","QBTS","BK4094","AMDW","BK4122","APPC","BK4608","TDUP","MUG","LU2087625088.SGD","BTDL","SNWV","RGTI","AMDY","MUD","MULL","BK4007","BK4588","RGTX","LU2290526834.HKD","AMUU","MUU","BK4139","BK4166","RGTU","XERS","BK4082","AMDC","RGTC","SKHA","IE00BZ9MQY76.HKD","SKDD","SKHL","IE00B894F039.SGD","PTLO","BTDR","SKHY","ECPG","QBY","SKUU","LU0056508442.USD","AMYY","LU0353189763.USD","SKHZ","BK4023","LU2360107168.USD","RGYY","BK4539","LU0097036916.USD","BK4209","LU1861220033.SGD","AMDG","SKHX","MIC","HYNX","VCYT","QBTZ","FIGG","DNUT","QBTX","SKHU","BK4613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681274009","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2681274009","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681274009?lang=en_us&edition=fundamental","pubTime":"2026-11-06 03:39","pubTimestamp":1793907597,"startTime":"0","endTime":"0","summary":"Sezzle  shares jumped 15% amid heavy trading after the company posted higher-than-expected Q3 adjusted earnings and revenue.Almost 1.56 million shares traded intraday, compared with a daily average of over 605,000.Xeris Biopharma  reported Q3 earnings and sales above analyst estimates and raised its full-year 2026 revenue outlook.Shares soared 25%, with intraday trading volume catapulting to nearly 8.83 million from a daily average of about 2.40 million.Precision BioSciences  said it priced an underwritten offering of 10.2 million shares at $7.75 per share and pre-funded warrants to buy up to 5.89 million shares at roughly $7.75 per pre-funded warrant, targeting gross proceeds of $125 million.Shares climbed 22% as intraday trading volume rose to roughly 2.24 million from the stock's daily average of about 253,000.Price: 156.93, Change: +20.24, Percent Change: +14.81","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4227","LU1861217088.USD","BK4139","LU2360107671.USD","LATR","SEZL","LU1861220207.SGD","XERS","BK4007","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681009504","title":"Xeris Biopharma Holdings, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2681009504","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681009504?lang=en_us&edition=fundamental","pubTime":"2026-11-06 03:22","pubTimestamp":1793906542,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings, Inc. reports results for the quarter ended September 30 - Earnings SummaryXeris Biopharma Holdings, Inc.XERS.OQreported quarterly adjusted earnings of 6 cents per share for t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL5N46M301:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681070384","title":"Xeris Biopharma up over 27%, on Track for Highest Close Since February 2019","url":"https://stock-news.laohu8.com/highlight/detail?id=2681070384","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681070384?lang=en_us&edition=fundamental","pubTime":"2026-11-06 00:02","pubTimestamp":1793894520,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings, Inc.  is currently at $13.33, up $2.87 or 27.44%--Would be highest close since Feb. 11, 2019, when it closed at $14.70--On pace for largest percent increase since May 16, 2022, when it rose 29.24%--Currently up three consecutive days; up 31.07% over this period--Best three day stretch since the three days ending Aug. 11, 2025, when it rose 31.15%--Up 69.81% year-to-date--Down 51.05% from its all-time closing high of $27.23 on Sept. 10, 2018--Up 72.89% from 52 weeks ago , when it closed at $7.71--Would be a new 52-week closing high--Up 151.98% from its 52-week closing low of $5.29 on March 24, 2026--Traded as high as $13.74; highest intraday level since Feb. 11, 2019, when it hit $15.00--Up 31.36% at today's intraday high; largest intraday percent increase since May 16, 2022, when it rose as much as 32.75%All data as of 11:00:46 AM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Xeris Biopharma up over 27%, on Track for Highest Close Since February 2019","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681813077","title":"Xeris Biopharma Shares Jump After Q3 Results Top Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2681813077","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681813077?lang=en_us&edition=fundamental","pubTime":"2026-11-05 23:12","pubTimestamp":1793891560,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings  shares surged 29% in Thursday trading after the company reported Q3 results that topped Wall Street estimates.In the three months ended Sept. 30, earnings were $0.06 per diluted share, compared with breakeven a year earlier.Three analysts polled by FactSet expected $0.02.Revenue rose to $107.2 million from $74.4 million a year earlier.Analysts projected $101.7 million.Xeris raised its 2026 revenue outlook to $395 million to $405 million from the previous range of $385 million to $390 million. Analysts expect $387.9 million.Price: 13.53, Change: +3.07, Percent Change: +29.30","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681078545","title":"Earnings Flash (XERS) Xeris Biopharma Posts Q3 EPS $0.06, vs. FactSet Est of $0.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2681078545","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681078545?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:45","pubTimestamp":1793882733,"startTime":"0","endTime":"0","summary":"Earnings Flash (XERS) Xeris Biopharma Posts Q3 EPS $0.06, vs. FactSet Est of $0.02","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681024768","title":"Xeris Biopharma Holdings Q3 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $106.267M Beat $101.517M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2681024768","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681024768?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:01","pubTimestamp":1793880112,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent.  The company reported quarterly sales of $106.267 million which","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62910927/xeris-biopharma-holdings-q3-adj-eps-0-06-beats-0-02-estimate-sales-106-267m-beat-101-517m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681790024","title":"Xeris Biopharma Q3 Net Income USD 11.29 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681790024","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681790024?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:01","pubTimestamp":1793880062,"startTime":"0","endTime":"0","summary":"BRIEF-Xeris Biopharma Q3 Net Income USD 11.29 MillionNov 05 (Reuters) - Xeris Biopharma Q3 product revenue USD 106.267 million vs. IBES estimate USD 101.5 million.Q3 EPS USD 0.06Q3 operating income USD 16.919 million","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXPJ4DTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681229540","title":"Xeris Biopharma: Raises 2030 Total Revenue Outlook to over $1 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2681229540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681229540?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:00","pubTimestamp":1793880003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXPJ4DTJ:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681002295","title":"Xeris Biopharma: Raises FY 2026 Total Revenue Guidance to $395 Mln-$405 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2681002295","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681002295?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:00","pubTimestamp":1793880003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXPJ4DTJ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681096978","title":"Xeris Biopharma President and COO Kevin McCulloch Reports Sale of 15,000 Common Shares for $153,487.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2681096978","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681096978?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:07","pubTimestamp":1793830076,"startTime":"0","endTime":"0","summary":"Xeris Biopharma President and COO Kevin McCulloch Reports Sale of 15,000 Common Shares for $153,487.50Xeris Biopharma President and Chief Operating Officer Kevin McCulloch sold 15,000 common shares on","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDLb68S9c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Xeris Biopharma President and COO Kevin McCulloch Reports Sale of 15,000 Common Shares for $153,487.50","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681096607","title":"Xeris Biopharma Grants Director Taddese 22,365 Restricted Stock Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2681096607","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681096607?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:06","pubTimestamp":1793830010,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Grants Director Taddese 22,365 Restricted Stock UnitsXeris Biopharma granted director Menassie Taddese 22,365 common shares on November 2, 2026.Taddese also received 31,499 stock optio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDLQPKmR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680144712","title":"What Xeris Biopharma Doubters Overlooked","url":"https://stock-news.laohu8.com/highlight/detail?id=2680144712","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680144712?lang=en_us&edition=fundamental","pubTime":"2026-11-03 13:34","pubTimestamp":1793684057,"startTime":"0","endTime":"0","summary":"XP-8121, Xeris Biopharma’s once weekly levothyroxine candidate, moved from concept to a clearly mapped Phase 3 plan during the period, giving holders something very specific to track beyond the existing endocrine portfolio. Investors who held Xeris Biopharma from the start of the year are up 38.4%, including dividends. If you were weighing a purchase on 1 January 2026, what had to be true in your mind about Recorlev, Gvoke and XP-8121 for that gain to feel reasonable?\nXeris Biopharma has...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/what-xeris-biopharma-doubters-overlooked","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/what-xeris-biopharma-doubters-overlooked","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","XP","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680275790","title":"Xeris Biopharma Appoints Menassie M. Taddese to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2680275790","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680275790?lang=en_us&edition=fundamental","pubTime":"2026-11-02 21:02","pubTimestamp":1793624569,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Appoints Menassie M. Taddese to Board of DirectorsXeris Biopharma appointed Menassie M. Taddese to its board, effective today. He will also serve on the Audit Committee.Taddese most re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL73wPMw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680529757","title":"Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2680529757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680529757?lang=en_us&edition=fundamental","pubTime":"2026-11-02 21:00","pubTimestamp":1793624402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUA5HQMDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.4192},{"period":"1month","weight":0.5035},{"period":"3month","weight":0.9168},{"period":"6month","weight":1.3277},{"period":"1year","weight":0.9715},{"period":"ytd","weight":0.9363}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.070057},{"month":2,"riseRate":0.625,"avgChangeRate":-0.03111},{"month":3,"riseRate":0.5,"avgChangeRate":-0.033138},{"month":4,"riseRate":0.5,"avgChangeRate":0.033714},{"month":5,"riseRate":0.75,"avgChangeRate":0.150943},{"month":6,"riseRate":0.5,"avgChangeRate":-0.023256},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.006473},{"month":8,"riseRate":0.666667,"avgChangeRate":0.189837},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.042191},{"month":10,"riseRate":0.555556,"avgChangeRate":0.00968},{"month":11,"riseRate":0.555556,"avgChangeRate":0.024272},{"month":12,"riseRate":0.625,"avgChangeRate":0.051713}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}